Morgan Stanley Portfolio holdings
Morgan Stanley, founded in 1935 by Henry Sturgis Morgan and Harold Stanley as a spin-off from J.P. Morgan & Co., is a leading global financial services firm headquartered in New York City. Initially focused on investment banking, it has evolved into a diversified powerhouse offering wealth management, institutional securities, and asset management services, catering to corporations, governments, institutions, and high-net-worth individuals. With a strong presence in mergers and acquisitions, underwriting, and trading, Morgan Stanley manages billions in assets and is known for its sophisticated financial advisory services. The firm has adapted to modern markets by expanding its digital offerings and wealth management division, notably through its 2020 acquisition of E*TRADE, solidifying its position as a Wall Street titan.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
XYZ
Block Inc
XYZ
|
+$1.53B |
| 2 |
Procter & Gamble
PG
|
+$1.01B |
| 3 |
iShares iBoxx $ High Yield Corporate Bond ETF
HYG
|
+$684M |
| 4 |
Zoom
ZM
|
+$534M |
| 5 |
Chewy
CHWY
|
+$491M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$5.07B |
| 2 |
ServiceNow
NOW
|
+$874M |
| 3 |
State Street Financial Select Sector SPDR ETF
XLF
|
+$776M |
| 4 |
Invesco QQQ Trust
QQQ
|
+$767M |
| 5 |
Apple
AAPL
|
+$719M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.32% |
| 2 | Healthcare | 10.4% |
| 3 | Consumer Discretionary | 8.1% |
| 4 | Communication Services | 7.82% |
| 5 | Financials | 7.44% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
NTZ
5076
Natuzzi
NTZ
$13.4M
| $144K | ﹤0.01% |
130,788
-4,000
| -3% | -$3.22K |
|
|
IMMP
5077
Immutep
IMMP
$56.3M
| $143K | ﹤0.01% |
132,085
+1,047
| +0.8% | +$1.08K |
|
5078
CNB Financial Corp
CCNE
$1.04B
| $142K | ﹤0.01% |
7,891
+3,450
| +78% | +$58.4K |
|
|
DRRX
5079
DELISTED
DURECT Corp
DRRX
| $142K | ﹤0.01% |
6,114
-11,711
| -66% | -$257K |
|
|
FLIC
5080
DELISTED
First of Long Island Corp
FLIC
| $142K | ﹤0.01% |
8,674
+5,094
| +142% | +$78.1K |
|
5081
Velocity Financial
VEL
$689M
| $142K | ﹤0.01% |
35,882
+22,298
| +164% | +$83.8K |
|
|
MARK
5082
DELISTED
Remark Holdings, Inc.
MARK
| $142K | ﹤0.01% |
+5,997
| New | +$92.2K |
|
|
HNP
5083
DELISTED
Huaneng Power Intl, Inc.
HNP
| $142K | ﹤0.01% |
9,378
-2,219
| -19% | -$32.5K |
|
5084
American Superconductor
AMSC
$1.42B
| $141K | ﹤0.01% |
17,282
+6,215
| +56% | +$40.6K |
|
5085
Choiceone Financial
COFS
$509M
| $141K | ﹤0.01% |
4,790
+1,257
| +36% | +$35.7K |
|
5086
LifeVantage
LFVN
$81.1M
| $141K | ﹤0.01% |
10,435
+5,955
| +133% | +$82.6K |
|
5087
Plumas Bancorp
PLBC
$427M
| $141K | ﹤0.01% |
6,368
-8,568
| -57% | -$166K |
|
|
CURO
5088
DELISTED
CURO Group Holdings Corp.
CURO
| $140K | ﹤0.01% |
17,054
-1,606
| -9% | -$11.4K |
|
5089
Clarus
CLAR
$123M
| $139K | ﹤0.01% |
12,046
+3,464
| +40% | +$35.2K |
|
|
FPRX
5090
DELISTED
Five Prime Therapeutics, Inc.
FPRX
| $139K | ﹤0.01% |
22,737
-37,437
| -62% | -$154K |
|
5091
Aethlon Medical
AEMD
$1.75M
| $138K | ﹤0.01% |
85
-2
| -2% | -$2.42K |
|
5092
FS Bancorp
FSBW
$319M
| $138K | ﹤0.01% |
7,126
-1,554
| -18% | -$30.3K |
|
5093
INNOVATE Corp
VATE
$111M
| $138K | ﹤0.01% |
4,132
+2,762
| +202% | +$78.1K |
|
5094
Willdan Group
WLDN
$1.04B
| $138K | ﹤0.01% |
5,480
+1,738
| +46% | +$40K |
|
|
PFBI
5095
DELISTED
Premier Financial Bancorp
PFBI
| $138K | ﹤0.01% |
10,721
+541
| +5% | +$6.71K |
|
5096
Princeton Bancorp
BPRN
$281M
| $136K | ﹤0.01% |
6,770
+2,453
| +57% | +$49.5K |
|
5097
Enliven Therapeutics
ELVN
$3.92B
| $136K | ﹤0.01% |
1,242
-34,847
| -97% | -$3.9M |
|
|
CMRX
5098
DELISTED
Chimerix, Inc.
CMRX
| $136K | ﹤0.01% |
43,880
+13,109
| +43% | +$33.9K |
|
|
BANX
5099
ArrowMark Financial
BANX
$198M
| $135K | ﹤0.01% |
8,475
-12
| -0.1% | -$198 |
|
5100
Miller Industries
MLR
$573M
| $135K | ﹤0.01% |
4,541
-6,534
| -59% | -$186K |
|
Similar funds
Morgan Stanley's Q2 2020 Portfolio in Review
As of Q2 2020, Morgan Stanley held 6,941 positions worth $452B, up 23% from $368B the previous quarter. Its ten largest holdings account for 17% of the portfolio.
Morgan Stanley's Q2 2020 filing shows 185 new, 3,288 increased, 2,645 reduced and 222 closed positions. Its largest new stake was Royalty Pharma: 6,205,186 shares worth $301M. The largest sale was State Street SPDR S&P 500 ETF Trust, an estimated $5.07B.
By sector, the portfolio is most concentrated in Technology at 19% of assets, up from 16% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- Morgan Stanley's largest Q2 2020 buy was Royalty Pharma: 6,205,186 shares worth $301M.
- Morgan Stanley added most to Block Inc in Q2 2020, an estimated $1.53B increase.
- Morgan Stanley's biggest Q2 2020 reduction was State Street SPDR S&P 500 ETF Trust, cutting an estimated $5.07B.
- Morgan Stanley fully exited Allergan plc in Q2 2020, selling an estimated $487M.
- Morgan Stanley's ten largest holdings make up 17% of its $452B portfolio in Q2 2020.
- Morgan Stanley opened 185 new positions and closed 222 in Q2 2020.
- Morgan Stanley's portfolio value rose 23% quarter-over-quarter to $452B.
Based on Morgan Stanley's 13F filing for Q2 2020, filed 14 Aug 2020.